CD8A and cancer: To further confirm this, rescue experiments were performed utilizing a CD8a monoclonal antibody (mAb) (Fig. 3f), the results of which proved that neutralization of CD8+ T cells significantly attenuated the inhibitory effect of sgTACC3 on the development of cancer cells (Fig. 3g‒i), further verifying that TACC3 promotes HCC deterioration partially in a CD8+ T-cell-dependent manner.